Cadonilimab (AK104), which functions as a PD‐1/CTLA‐4 bispecific antibody, is under investigation in a Phase 1b/2 clinical trial in conjunction with anlotinib for patients with advanced NSCLC [80]. Here, PDCD1 is linked to non-small cell lung carcinoma.